ClinicalAtrial FibrillationHigh-power, short-duration atrial fibrillation ablations using contact force sensing catheters: Outcomes and predictors of success including posterior wall isolation
Introduction
Atrial fibrillation (AF) ablation has become standard treatment of patients with AF. Ablation therapy reduces AF burden and alleviates symptoms. In patients with heart failure, it improves survival and reduces hospitalizations.1 Improvements in the procedural aspects of AF ablation include better 3-dimensional mapping systems, use of irrigated-tip radiofrequency (RF) ablation catheters, the introduction of contact force (CF) measurements, and methods for determining lesion formation, such as loss of pace capture during ablation2 and monitoring the Lesion Index (LSI, St Jude, St Paul, MN) and the Ablation Index (AI, Biosense Webster, Diamond Bar, CA).3 Increasing use of high-power, short-duration (HPSD) RF ablation can shorten procedure and fluoroscopy times and may improve outcomes.2,4, 5, 6 HPSD ablations have been shown to be at least as safe as other types of RF ablation.7 Studies comparing CF to non-CF ablation have been reported,8,9 but only a few have reported long-term outcomes related to the use of both CF and HPSD ablation. Most studies of CF sensing have reported on patients with paroxysmal AF but only a few have reported on patients with persistent AF.10,11 In the present study, we examined long-term outcomes in a cohort of patients with all types of AF undergoing HPSD ablation using CF catheters. We examined procedural data, clinical outcomes, predictors of outcome, and results of redo ablations.
Section snippets
Patient population
Study subjects consisted of consecutive symptomatic patients undergoing initial AF ablation at Sequoia Hospital (Redwood City, CA) from March 27, 2014, to December 31, 2017. Patients who previously had undergone AF ablation or a surgical AF procedure were excluded. Patients with a previous right atrial cavotricuspid isthmus (CTI) flutter ablation were included. All patients signed written informed consent for the ablation procedure. Data collection was prospective, analysis was retrospective,
Patient population
The subjects of this study were 1250 consecutive patients undergoing 1433 ablations for symptomatic AF. AF was paroxysmal in 447 (35.7%), persistent in 707 (56.6%), and longstanding in 96 (7.7%). Mean age was 66.6 ± 10.5 years, and 386 patients (30.9%) were female. Average LA size was 4.26 ± 0.66 cm. AF was present for 5.5 ± 6.9 years, and patients had not responded to 1.00 ± 0.89 AADs before ablation. Duration of postablation follow-up was 2.1 ± 1.0 years. Table 1 lists demographics for the
Discussion
Several studies have examined AF ablation outcomes using CF sensing catheters8,9 or HPSD ablations.2,4, 5, 6 The present study is the first large real-world evaluation of the combination of HPSD and CF sensing and examination of outcomes and predictors of success. The study found that traditional factors found with non-CF catheters, such as older age, female gender, more persistent AF, and larger LA size, still were predictive of a poorer outcome. The study also found that the particular CF
Conclusion
This study examines the procedural details and long term outcomes in a large cohort of patients undergoing AF ablation with HPSD and CF. We found 6 predictors of outcome including the catheter used and whether PWI was done. For redo ablations both the number of reconnected veins and the type of AF were predictors of outcomes.
Acknowledgments
Patricia Barberini, RN, Cynthia Lebsack, PharmD, and Glenda Rhodes assisted with data and manuscript management.
References (14)
- et al.
Novel ablative approach for atrial fibrillation to decrease risk of esophageal injury
Heart Rhythm
(2008) - et al.
Low complication rates using high power (45 to 50W) for short duration for atrial fibrillation ablations
Heart Rhythm
(2019) - et al.
The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study
Heart Rhythm
(2012) - et al.
Contact force sensing for ablation of persistent atrial fibrillation: a randomized, multicenter trial
Heart Rhythm
(2018) - et al.
for the POBI-AF Investigators. The electrical isolation of the left atrial posterior wall in catheter ablation of persistent atrial fibrillation
JACC Clin Electrophysiol
(2019) - et al.
for the CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure
N Engl J Med
(2018) - et al.
Atrial fibrillation ablation using very short duration 50 W ablations and contact force sensing catheters
J Interv Card Electrophysiol
(2018)
Cited by (0)
This research did not receive any funding from agencies in the public, private, or not-for-profit sectors. Dr Winkle has been an investor in Farapulse; and an investigator for Abbott. Dr Mead has served on the advisory board for Medtronic and iRhythm. Dr Engel has served on the advisory board of Medtronic. Dr Brodt has served as a consultant for AtriCure. All other authors have reported that they have no conflicts relevant to the contents of this paper to disclose.